Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent

Next Previous
X
Search
Trial Profile

TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Coronary disorders; Myocardial infarction; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms TAXUS-IV
  • Sponsors Boston Scientific Corporation

    • Most Recent Events

    • 23 Apr 2014 Data cleaning 4: Deleted descriptors - Drug-eluting-stents (non drug), Controlled-release-drugs (delivery system), coronary-stenting (non drug procedure), GPIIb-IIIa-antagonists (drug class), cost-effectiveness, cost-utility, Ischaemia etc.
    • 25 Sep 2008 FDA approval received for TAXUS stent.
    • 22 Oct 2007 Boston Scientific announced final 5-year follow-up data.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top